AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Go back to AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program| AbbVie (NYSE: ABBV) | Delayed: 264.52 -0.44 (0.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.96 | 52 Week High | $68.12 | |||
| Open | $263.99 | 52 Week Low | $50.71 | |||
| Day High | $266.04 | P/E | 57.38 | |||
| Day Low | $262.07 | EPS | $4.61 | |||
| Volume | 3,883,790 | |||||
| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 8.06 -2.66 (24.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.72 | 52 Week High | $25.00 | |||
| Open | $8.29 | 52 Week Low | $7.07 | |||
| Day High | $8.64 | P/E | N/A | |||
| Day Low | $7.77 | EPS | $0.00 | |||
| Volume | 5,445,045 | |||||
